Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

With a positive readout in hand, Zai Lab says it's “moving swiftly” to file an approval application for KarXT in China by early 2025. For Bristol Myers Squibb's newly approved schizophrenia ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (WBAG:BMYS) from Market Perform to Outperform. There are 3,419 funds or institutions ...

Related: Bristol Myers Squibb's stock jumps on schizophrenia-drug ... The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces ...